Project Grant R43AI197694
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ames, IA 50014, USA
Similar Awards
- Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $307,074 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop HIVE-SEQ, a novel omics platform for profiling single HIV-infected cells. HIVE-SEQ integrates the intact proviral DNA assay with single-cell and single-nucleus multi-omic profiling to identify and characterize cells carrying viable HIV proviruses across diverse tissues without requiring viral...
- The National Institute of Allergy and Infectious Diseases awarded Keylicon Biosciences Inc. $314,363 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a low-dose multivalent self-amplifying RNA (saRNA) influenza vaccine. Keylicon will engineer a saRNA construct encoding four World Health Organization-recommended influenza antigens and design modified nucleotide formulations to enhance antigen production while suppressing innate immune...
- Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...
- The National Institute of Allergy and Infectious Diseases awarded Orlance, Inc. $598,837 on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals. Orlance will advance a DNA vaccine delivery platform using its MACH-1 gene gun technology, which administers room-temperature stable DNA and RNA vaccines directly into epidermal cells. The approach aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $909,998 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize antibody-mediated establishment of an SIV reservoir using an art-free approach. The project, designated R01AI198034, runs through January 31, 2031, with place of performance in Atlanta, Georgia. The research employs adeno-associated virus (AAV) vectors to deliver broadly neutralizing...
- The National Institute of Allergy and Infectious Diseases awarded Vivid Bioinnovations, PBC $299,991 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a spatially resolved single-cell DNA sequencing platform for spatial genomics with application to HIV reservoir mapping. The recipient will develop the first commercially viable spatial genomics platform integrating hydrogel-based spatial barcoding, droplet microfluidics, and Bayesian...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,552 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nanoplatform for nasal universal influenza vaccines. The project addresses limitations in current cross-protective influenza vaccines by creating a nasal delivery system using nanosized extracellular vesicles (EVs) that display inverted hemagglutinin (HA)...